Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., develops and commercializes innovative immunotherapeutics for the treatment of cancer.
At Oxis, we develop and commercialize innovative immunotherapies for the treatment of cancer and other unmet medical needs.
OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate.
OXS-2175 is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer.
OXS-4235 is a small molecule therapeutic candidate that targets the treatment of multiple myeloma and associated osteolytic lesions.